SAB Biotherapeutics Appoints New Independent Board Chair, Directors

SAB Biotherapeutics ( (SABS) ) has shared an announcement.

On January 5, 2026, SAB Biotherapeutics appointed veteran biopharma executive David Zaccardelli, Pharm.D., and rheumatologist and drug development leader Rita Jain, M.D., as Class II directors, with Zaccardelli becoming Chair of the Board and both serving until the 2026 annual meeting. The appointments, announced publicly on January 7, 2026, follow RA Capital Healthcare Fund’s nomination rights stemming from SAB’s July 2025 private placement and keep CEO Samuel J. Reich on the board while shifting the chair role to an independent industry operator with a track record of leading companies through major growth, approvals, and M&A. Both Zaccardelli and Jain bring deep experience in late-stage development, commercialization, and autoimmune and inflammatory disease drug development, signaling SAB BIO’s intent to strengthen governance and board-level expertise as it advances its lead asset SAB-142 through registrational trials and prepares for potential commercialization in type 1 diabetes, a move likely to be closely watched by investors focused on execution risk and value creation in autoimmune therapeutics.

The most recent analyst rating on (SABS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Spark’s Take on SABS Stock

According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.

The score is held down primarily by deteriorating financial performance (sharp revenue decline, ongoing losses, and negative free cash flow). Technicals are modestly supportive with the stock above key longer-term moving averages, but valuation is constrained by unprofitability and the new ATM financing adds dilution risk despite improving access to capital.

To see Spark’s full report on SABS stock, click here.

More about SAB Biotherapeutics

SAB Biotherapeutics (SAB BIO) is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders. Its lead candidate, SAB-142, is being developed as a disease-modifying therapy for autoimmune type 1 diabetes, with the aim of changing the treatment paradigm by delaying onset and potentially preventing progression of Stage 3 T1D, leveraging a proprietary Tc-Bovine-based platform to generate fully human antibodies without human donors or convalescent plasma.

Average Trading Volume: 257,002

Technical Sentiment Signal: Buy

Current Market Cap: $178M

See more insights into SABS stock on TipRanks’ Stock Analysis page.